Adverum Biotechnologies Change in Accounts Receivable 2013-2025 | ADVM

Adverum Biotechnologies change in accounts receivable from 2013 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Adverum Biotechnologies Change in Accounts Receivable 2013-2025 | ADVM

Adverum Biotechnologies change in accounts receivable from 2013 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.1B
Amgen (AMGN)$155.2B
Gilead Sciences (GILD)$148.2B
Vertex Pharmaceuticals (VRTX)$94B
Bristol Myers Squibb (BMY)$93.5B
CSL (CSLLY)$82.7B
GSK (GSK)$77.1B
Regeneron Pharmaceuticals (REGN)$59.7B
Alnylam Pharmaceuticals (ALNY)$57.5B
Argenex SE (ARGX)$40.5B
BioNTech SE (BNTX)$26.8B
Insmed (INSM)$23.2B
Royalty Pharma (RPRX)$21.1B
Biogen (BIIB)$19.2B
Incyte (INCY)$15.3B
Illumina (ILMN)$14.5B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.7B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Moderna (MRNA)$10.2B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Roivant Sciences (ROIV)$7.8B
Exact Sciences (EXAS)$7.8B
Halozyme Therapeutics (HALO)$7.8B